Drug intelligence / Profile preview

GIM-0915

Development stage: Preclinical
Lead developer: Georgiamune
Modality: Small Molecules

Overview

GIM-0915 is a small molecule drug candidate developed by Georgiamune for the treatment of neoplasms (cancers). As of March 2025, it is in preclinical development. The specific mechanism of action, molecular target(s), and detailed pharmacological profile have not been publicly disclosed. Georgiamune specializes in developing immunomodulatory therapies aimed at reprogramming immune responses to fight cancer and autoimmune diseases[2][9].

Beyond the preview

Go deeper on GIM-0915.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIM-0915.

Explore the full profile